- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Raymond James initiates Polaryx Therapeutics stock with strong buy | 1 | Investing.com | ||
| Do | Raymond James startet Coverage für Polaryx Therapeutics mit "Strong Buy" und sieht 170 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 27.07. | Lucid Capital startet Coverage für Polaryx mit Kaufempfehlung - Potenzial bei Therapie für seltene Krankheiten | 1 | Investing.com Deutsch | ||
| 27.07. | Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential | 2 | Investing.com | ||
| 24.07. | Polaryx Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 17.07. | Polaryx Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 03.07.2026 | 518 | Xetra Newsboard | The following instruments on XETRA do have their first trading 03.07.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.07.2026
Aktien
1 JP3100020001 Archion Corp.
2 US73110F1003... ► Artikel lesen | |
| POLARYX THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.05. | Polaryx Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Polaryx Therapeutics sichert sich 10 Millionen US-Dollar über PIPE-Finanzierung | 1 | Investing.com Deutsch | ||
| 28.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial | 1 | GlobeNewswire (USA) | ||
| 14.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards | 4 | GlobeNewswire (USA) | ||
| 21.04. | FDA grants fast track status to Polaryx's PLX-200 for three rare diseases | 2 | Investing.com | ||
| 21.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial | 353 | GlobeNewswire (Europe) | PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs,... ► Artikel lesen | |
| 15.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | 1 | GlobeNewswire (USA) | ||
| 17.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) | 303 | GlobeNewswire (Europe) | Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX-200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx... ► Artikel lesen | |
| 12.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events | 2 | GlobeNewswire (USA) | ||
| 27.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders | 1 | GlobeNewswire (USA) | ||
| 17.02. | Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans | 1 | Benzinga.com | ||
| 17.02. | Morning Market Movers: Polaryx Therapeutics, JIADE, ZIM Integrated Shipping Services, Masimo Corporation See Big Swings | 948 | AFX News | WASHINGTON (dpa-AFX) - At 7:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 02.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" | 392 | GlobeNewswire (Europe) | PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,950 | -0,14 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,640 | +1,69 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | -0,17 % | Ocugen präsentiert spätphasige Gentherapie-Strategie für Augenerkrankungen | ||
| NUREXONE BIOLOGIC | 0,296 | -0,34 % | NurExone stellt Weichen für den US-Markt: Exklusive GMP-Partnerschaft soll Produktion und Kommerzialisierung beschleunigen | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,024 | +2,56 % | PacBio im Umbruch: Klinisches Wachstum kompensiert kurzfristige Belastungen | ||
| REDHILL BIOPHARMA | 0,580 | -0,70 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,321 | -7,90 % | Onco-Innovations Limited: Onco-Innovations Advances ONC010 Polymer Development with Identification of Non-Tin Catalyst and Provides Integrated Update | ||
| NOVOCURE | 14,565 | 0,00 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,500 | -2,30 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ROCKET PHARMACEUTICALS | 2,880 | -4,32 % | Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus | ||
| PALISADE BIO | 2,145 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development | Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,831 | 0,00 % | ONCOLYTICS BIOTECH INC - 10-Q, Quarterly Report | ||
| OUTLOOK THERAPEUTICS | 0,657 | +0,46 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA | The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA... ► Artikel lesen | |
| REGENXBIO | 9,254 | -0,56 % | H.C. Wainwright lowers Regenxbio stock price target on equity offering | ||
| OMEROS | 15,000 | +1,01 % | OMEROS CORP - S-8, Securities to be offered to employees in employee benefit plans |
Das Unternehmen POLARYX THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,110 Euro und damit +9,90 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLARYX THERAPEUTICS INC finden Sie auf Wallstreet Online.